Q-omics provides the consensus-scored MAP7D2 profile across patient tissues and cancer cell-line models. MAP7D2 expression is associated with patient survival in 22 of 34 cancer types, with the highest sampling consensus in STAD. Among the 18 cancer types available for tumor–normal comparison, MAP7D2 is differentially expressed in 11, with the highest sampling consensus in KIRC. Additionally, MAP7D2 protein abundance shows 16,294 significant protein co-abundance associations, with the highest sampling consensus in GBM. Together, these results highlight STAD, KIRC, and GBM as cancer lineages where MAP7D2 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for MAP7D2 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes MAP7D2 survival associations across molecular data types. MAP7D2 RNA expression shows survival associations in the most cancer types (22), followed by mutation status (5) and mass-spec protein abundance (3). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible MAP7D2 RNA expression–survival associations across cancer types. High MAP7D2 expression shows unfavorable associations in STAD, UCEC and ESCA, but favorable associations in PAAD, LUAD and KIRC. The STAD Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p < 0.001). Together, the overview and detailed table identify STAD as the clearest survival context for MAP7D2 RNA expression.
This table summarizes MAP7D2 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 11, while mass-spec protein shows differences in 3. The strongest signals are observed in KIRC for RNA and LUAD for protein.
This table ranks reproducible tumor–normal expression differences for MAP7D2. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. MAP7D2 shows lower tumor expression in KICH and STAD and higher tumor expression in KIRC, LUAD, HNSC and THCA. The KIRC box plot shows higher MAP7D2 RNA expression in tumor versus normal tissue (log2 FC = +1.727, t-test p < 0.001).
This table shows molecular features associated with MAP7D2 in patient tissues and cancer cell lines. In patient samples, MAP7D2 shows the broadest associations at the RNA and protein expression levels, with GBM recurring as the lineage with the largest associated feature set. In cancer cell lines, MAP7D2 RNA and mutation anchors are most strongly linked to RNA-expression features, especially in LUNG_NSCLC_LUAD, while CRISPR and shRNA rows add functional-dependency signals in SOFT_TISSUE and BONE.
